EGFR and non-small cell lung carcinoma: Further, F127ZIF‐8AB680 significantly enhanced the therapeutic efficacy of anti‐PD‐1 in mouse models, which represents a promising strategy for improving the therapeutic outcomes of EGFR‐mutant NSCLC patients suffering from immunotherapy resistance.